Biomarkers and Precision Medicine Community (BPMC)

Precision Medicine in Oncology

·         How does AI/ML enable the development of on-demand, neoantigen-based cancer therapies?  Challenges with the advent of AI and personalized cancer medicine.

·         How does the path for approval vary between personalized cancer vaccines and traditional therapies?

·         Challenges in Translational Research – the translatability crisis

·         Suggestions to improve Translational Research

Discussion Leaders:

Guilhem Richard (EpiVax Therapeutics) and Attila Sayhan (Brown University)

Organized by:  

Vibha Jawa (BMS), Karen Quadrini (Passage Bio) and Carmen Fernández-Metzler (PharmaCadence)